Regeneron/Sanofi cholesterol drug gets FDA priority review

January 26, 2015 6:15 AM

4 0

(Reuters) - Regeneron Pharmaceuticals on Monday said U.S. health regulators accepted its application to review a potent cholesterol drug on a priority basis, potentially giving it the upper hand in a fierce race with Amgen to bring a new medicine from the promising class to market.

Regeneron, which is developing the drug, alirocumab, in partnership with Sanofi, said the target date for a Food and Drug Administration approval decision was July 24, following a six-month review period.

Also read: More than 10 million devices helped take down the internet on Friday

Read more

To category page